04/19/2026
Yesterday, President Trump signed a groundbreaking executive order that could change mental health treatment in America forever.
For the first time, the federal government is investing $50 million into psychedelic medicine research and opening pathways for patients who've run out of options.
Here's what you need to know:
🍄 Psilocybin — showing 73% treatment response for OCD
💊 M**A — 67% of PTSD patients achieved full remission
🧠 Ketamine — already available in clinics nationwide
🌿 Ibogaine — the first drug ever to show relief for traumatic brain injury symptoms
These aren't party drugs. These are FDA-tracked, clinically supervised treatments being studied at Johns Hopkins, Stanford, and NYU, and they're giving hope to millions with depression, PTSD, addiction, and anxiety who haven't responded to traditional medication.
If you or someone you love is struggling, there are options. Clinical trials are free. Ketamine clinics are open now. And this new legislation is accelerating access.
Knowledge is power.
_______________________
The president just signed the most significant mental health executive order in a generation. Here's what it means for you.
👇👇👇
WHAT JUST HAPPENED
On April 18, 2026, President Trump signed an executive order that could change the future of mental health treatment in America.
The order directs $50 million through ARPA-H (Advanced Research Projects for Health) into psychedelic medicine research. Three psychedelic compounds were added to the FDA's National Priority Voucher program to fast-track their review. And a Right to Try pathway was opened so terminally ill and treatment-resistant patients can access investigational psychedelic drugs, including ibogaine, while clinical trials continue.
This is not recreational drug legalization.
This is supervised, clinical, medical treatment developed at the same institutions that have led American medicine for a century.
FDA Commissioner Marty Makary, HHS Secretary Robert F. Kennedy Jr., and podcast host Joe Rogan joined Trump in the Oval Office for the signing. Rogan said he texted Trump about the benefits of ibogaine, and Trump replied, "Sounds great. Do you want FDA approval? Let's do it."
The order also directs the Attorney General to begin rescheduling reviews of psychedelic compounds as soon as they successfully complete Phase 3 clinical trials. The drugs remain Schedule I for now — but the door is open.
Let's talk about what these medicines actually are.
WHAT ARE THESE DRUGS?
🍄 PSILOCYBIN
This is the active compound in certain mushrooms. It's being studied for treatment-resistant depression, OCD, end-of-life anxiety in terminal patients, and addiction. Johns Hopkins, NYU, and Yale are leading the research. Compass Pathways ran a Phase 3 clinical trial showing significant improvement in patients who had failed every other treatment. Psilocybin has received an FDA Breakthrough Therapy designation, meaning the agency recognizes its potential to be a substantial improvement over existing treatments.
💊 M**A
Yes, the compound once known as ecstasy. But in clinical settings, it's administered in pure pharmaceutical form under direct therapist supervision, nothing like street drugs. MAPS (the Multidisciplinary Association for Psychedelic Studies) found that 67 to 71 percent of PTSD patients who received M**A-assisted therapy no longer met the diagnostic criteria for PTSD. Compare that to roughly 30 to 40 percent with traditional therapy alone. It's being studied primarily for PTSD, especially in veterans and first responders who've been through things most of us can't imagine.
🌿 IBOGAINE
This is the compound at the center of Trump's executive order. Ibogaine is derived from the root bark of the African iboga plant, used for centuries by the Bwiti people of Central Africa in spiritual ceremonies. Stanford University published a groundbreaking study in Nature Medicine, finding that ibogaine, combined with magnesium for cardiac protection, produced dramatic improvements in veterans with traumatic brain injury. Lead researcher Dr. Nolan Williams said, "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury. The results are dramatic." The study of 30 Special Operations veterans showed significant reductions in PTSD, depression, anxiety, and suicidal ideation. Ibogaine is also being studied for opioid and alcohol addiction. Important: ibogaine carries cardiac risks and must only be administered in supervised medical settings with cardiac monitoring.
💉 KETAMINE
This is the only psychedelic-adjacent medicine already legally available in the United States right now. The FDA-approved nasal spray version, called Spravato (esketamine), exists for treatment-resistant depression. Ketamine infusion clinics currently operate in all 50 states. This is something you could access today if you and your doctor decide it's appropriate. Costs range from $75 to $150 per oral session to $400 to $800 per IV infusion.
🔬 L*D (Lysergic Acid Diethylamide)
Being studied in clinical trials for anxiety disorders, cluster headaches, and depression. Research is at an earlier stage than psilocybin and M**A, but showing real promise. L*D was specifically named in Trump's executive order alongside the other compounds.
🧠 HOW DO THEY ACTUALLY WORK IN YOUR BRAIN?
Here's the simplest way I can explain it.
Think of your brain like a forest with well-worn trails — the same paths you walk every day. In depression, PTSD, and addiction, those paths become deep ruts. Rigid loops of negative thinking, fear, and craving that your brain gets stuck in.
These compounds primarily work on serotonin receptors in the brain. They temporarily quiet a part of your brain called the Default Mode Network, your inner narrator, the voice of self-criticism, rumination, and worry, and allow your brain to form new connections between regions that don't normally talk to each other.
Scientists call this neuroplasticity.
In simple terms: these drugs don't numb you. They don't mask your symptoms. They help your brain build new, healthier pathways. Many patients describe having a single session that feels like years of therapy compressed into a few hours.
The Stanford ibogaine study actually measured this using brain scans. They found increased theta brain waves (associated with neuroplasticity and cognitive flexibility) and reduced cortical complexity (associated with lowering the heightened stress response seen in PTSD).
This is not mystical. This is measurable neuroscience.
✅ WHO CAN THIS HELP?
The conditions currently being studied include:
Treatment-resistant depression affects over 14 million American adults, who have a serious mental illness. 8 million are on prescription medication that may not be working well for them.
PTSD, especially in veterans. More than 6,000 U.S. veterans die by su***de every year. Trump himself noted during the signing: "Our veterans are having a tremendous hard time."
More than 5 million Americans are addicted to opiates. Joe Rogan stated during the signing that "with one dose of ibogaine, more than 80 percent are free of that."
OCD (Obsessive-Compulsive Disorder)
Traumatic brain injury (TBI) — the Stanford study is the first to show a drug can address TBI symptoms
End-of-life anxiety in terminal patients
⚠️ IMPORTANT CAVEAT: These are NOT for everyone. People with a personal or family history of schizophrenia, bipolar I disorder, or active psychosis should NOT use psychedelics. These medicines must be administered under clinical supervision. Period.
📍 WHERE CAN YOU GET TREATMENT RIGHT NOW?
This is the practical part. Here's what's actually available today:
Ketamine clinics — available in all 50 states right now. Search "ketamine clinic near me" or visit the American Society of Ketamine
Physicians' directory online.
Psilocybin therapy is legally available in Oregon and Colorado through licensed service centers. You do not need to be a resident of those states.
Clinical trials — these are FREE to participants. Go to ClinicalTrials.gov and search for "psilocybin," "M**A," "ibogaine," or "psychedelic" and filter by your state. This is how you can access cutting-edge treatment at no cost.
Johns Hopkins Center for Psychedelic and Consciousness Research is one of the leading programs in the world. They are actively enrolling for clinical trials.
MAPS — the leading organization for M**A therapy research. Visit their website for trial enrollment information.
💰 WHAT DOES IT COST?
Ketamine (oral): $75 to $150 per session
Ketamine (IV infusion): $400 to $800 per session
Spravato (FDA-approved nasal spray): $600 to $900 per session, sometimes covered by insurance
Psilocybin therapy (Oregon/Colorado): $1,500 to $3,500 per session
Clinical trials: FREE
International ibogaine treatment: $5,000 to $12,000+
Most psychedelic therapies are NOT yet covered by insurance, except Spravato. This is expected to change as more FDA approvals come through. Trump's executive order directing the Attorney General to begin rescheduling reviews is a critical step toward insurance coverage.
⚠️ WHAT ARE THE RISKS? LET'S BE HONEST.
These are powerful medicines, not party drugs. I'd be doing you a disservice if I didn't talk about this.
Psychological distress during sessions is possible. These experiences can surface difficult memories and emotions. That's actually part of the therapeutic process, but it's also why professional supervision matters.
Cardiac risks, especially with ibogaine. There are documented deaths linked to cardiac events during unsupervised ibogaine use. The Stanford protocol specifically includes magnesium co-administration and cardiac monitoring to address this.
Drug interactions and serious contraindications exist with SSRIs, MAOIs, and other medications. You cannot just stop your current medication and start psychedelic therapy. This must be managed by a doctor.
The danger of unsupervised use is real. Underground ceremonies, unregulated retreats, and self-administered doses carry genuine risks. This is why clinical supervision matters. This is why the executive order focuses on research, FDA pathways, and medical protocols, not legalization for recreational use.
Never attempt these treatments outside of a licensed medical or therapeutic setting.
💡 WHY THIS MATTERS
For millions of Americans who have tried every antidepressant, every therapy, every approach, and still struggle every single day, this executive order represents real hope.
Not hype. Not counterculture. Science.
The same institutions that have led American medicine, Johns Hopkins, Stanford, NYU, Yale, are now telling us these medicines work. Measurably. Reproducibly. In peer-reviewed, published research.
And for the first time, the federal government is listening.
FDA Commissioner Marty Makary said it clearly during the signing: "This is an unmet public health need, and there are potentially promising treatments. That's why there is a sense of urgency around this."
Dr. Mehmet Oz, the CMS Administrator, called it "an entire paradigm shift away from a one-pill-a-day model, which has failed so many."
This isn't about politics. This is about people who are suffering and the science that might help them.
If you or someone you love is struggling:
📞 988 Su***de and Crisis Lifeline — call or text 988
📞 Veterans Crisis Line — call 988, then press 1
You are not alone. Help exists. And it's getting better.
⚕️ MEDICAL DISCLAIMER
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented here is intended to increase public awareness of emerging research in psychedelic medicine and should not be used as a substitute for professional medical guidance.
If you are considering any form of psychedelic-assisted therapy, please consult a licensed clinical psychologist, psychiatrist, or other qualified healthcare professional before making any decisions about your mental health treatment.
Never start, stop, or change any medication or treatment plan without the direct supervision of your healthcare provider. If you are in crisis, please get in touch with the 988 Su***de & Crisis Lifeline (call or text 988) or the Veterans Crisis Line (1-800-273-8255, Press 1).
I'd love to hear your thoughts. Did you know about psychedelic medicine research before today? Would you consider it for yourself or a loved one? Drop your thoughts below 👇
**A
